This Market Spotlight report covers the cervical cancer market, comprising key pipeline and marketed drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
- The author estimates that in 2016, there were 556,200 incident cases of cervical cancer in females worldwide, and expects that number to increase to 609,500 incident cases by 2025.
- Incidence cases are highest in Asia, and lowest in the Oceania region. Roche’s Avastin (bevacizumab) and Amgen’s Mvasi (bevacizumab), which target vascular endothelial growth factor; Novartis’s Hycamtin (topotecan hydrochloride), a topoisomerase I inhibitor; and Pinnacle’s Photofrin (porfmer sodium), a photodynamic therapy, are the only marketed drugs available for cervical cancer. The majority of the marketed drugs are administered via the intravenous route.
- Therapies in mid-to-late-stage development for cervical cancer focus on a variety of targets. The majority of the drugs in mid-tolate-stage development for cervical cancer are administered via the intravenous route, with the remainder being intramuscular, intranasal, subcutaneous, and oral.
- High-impact upcoming events for drugs in the cervical cancer space include topline Phase II and Phase III trial results. Licensing and asset acquisition activity involving cervical cancer drugs has been weak during 2012-17, with only 11 deals over this time period. The $727.5m license agreement between Inovio and MedImmune for the exclusive rights to develop and market Inovio's INO-3112 was the largest deal during 2012-17.
- The clinical trials distribution across Phase I-IV indicates that the majority of trials for cervical cancer have been in early and midphases of development, with 95% of trials in Phase I-II, and only 5% in Phase III-IV.
- The US has a substantial lead in the number of cervical cancer clinical trials globally. The UK leads the major EU markets, while South Korea has the top spot in Asia.
- Clinical trial activity in the cervical cancer space is dominated by ongoing trials. AstraZeneca and Roche have the highest number of ongoing clinical trials for cervical cancer, with 11 and eight ongoing trials, respectively.
- AstraZeneca leads industry sponsors with the highest number of clinical trials for cervical cancer, followed by Roche.
Approvals by country
KEY UPCOMING EVENTS
LICENSING AND ASSET ACQUISITION DEALS
Alligator And Aptevo Seal Immuno-Oncology Pact
Advaxis Zips Listeria/Opdivo Combo Straight To Registrational Cervical Cancer Trial
CLINICAL TRIAL LANDSCAPE
List of Figures
Figure 1: Trends in incident cases of cervical cancer, 2016-25
Figure 2: Pipeline drugs for cervical cancer in the US
Figure 3: Pipeline drugs for cervical cancer, by company
Figure 4: Pipeline drugs for cervical cancer, by drug type
Figure 5: Pipeline drugs for cervical cancer, by drug classification
Figure 6: Key upcoming events in cervical cancer
Figure 7: Licensing and asset acquisition deals in cervical cancer, 2013-18
Figure 8: Parent patents in cervical cancer
Figure 9: Clinical trials in cervical cancer
Figure 10: Top 10 drugs for clinical trials in cervical cancer
Figure 11: Top 10 companies for clinical trials in cervical cancer
Figure 12: Trial locations in cervical cancer
Figure 13: Cervical cancer trials status
Figure 14: Cervical cancer trials sponsors, by phase
List of Tables
Table 1: Incident cases of cervical cancer, 2016-25
Table 2: Marketed drugs for cervical cancer
Table 3: Approvals by country for cervical cancer
Table 4: Pipeline drugs for cervical cancer in the US
Table 5: Historical global sales, by drug ($m), 2012-16
Table 6: Forecasted global sales, by drug ($m), 2017-22